Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Date:1/4/2012

SAN FRANCISCO, Jan. 4, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 30th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Wednesday, January 11, 2012 at 8:30 a.m. Pacific time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 12, 2012.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled seven approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. Nektar has an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects. NKTR-181, a novel mu-opioid analgesic, has completed
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
2. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Therapeutics to Webcast R&D Day on November 12th
5. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Retirement of Irwin Lerner from Board of Directors
8. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VANCOUVER , Dec. 22, 2014 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development of ... paper out of the University of Calgary in conjunction ... North Carolina, which further validates the company,s ongoing clinical ... the effects of pattern baldness. The paper ...
(Date:12/22/2014)... December 22, 2014 ITRA Global, one ... occupiers of commercial real estate, has further expanded its ... in Perth and Brisbane, Western Australia, reports Mylinda Vick, ... , ITRA Global / ACORPP (Australian Corporate Property ... consultancy company providing property services to a wide range ...
(Date:12/19/2014)... Naurex Inc., a biopharmaceutical company leveraging its ... the central nervous system, today announced that Norbert ... present at the 33 rd annual J.P. Morgan ... 3:00 p.m. PST on Tuesday, January 13, 2015, at ... Calif. About Naurex Inc. ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... pharmacies, has an expanded team of Regional Pharmaceutical ... for prescriber offices in their regions, with specific ... have a variety of Regional Pharmaceutical Care Liaisons ... in hepatitis C help prescribers understand all the ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... Md., Nov. 10 Spherix Incorporated,(Nasdaq: SPEX ) ... to transfer the listing of its common stock from ... common stock is expected to,commence trading on the Nasdaq ... Capital Market is one of three market tier designations ...
... Call Today To Discuss the Data and Ongoing ... Clinical Development Programs, RICHMOND, ... today top-line data from its,SB-509-601 clinical trial, one of Sangamo,s three ... for diabetic,neuropathy (DN). The data demonstrate that repeat administration of the,drug ...
... /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ... of high-quality,pharmaceutical grade glucose products in China, today ... three months ended September 30, 2008,after the close ... 2008.,Management will conduct a conference call on Friday, ...
Cached Biology Technology:Spherix Transfers Stock Listing to Nasdaq Capital Market 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 2Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 3
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... 15, 2012   ICAP Patent Brokerage , a division of ... and organizer of ICAP Ocean Tomo Auctions, is offering for ... John H. Messing. The lot will be included in the ... at Terranea Resort near Los Angeles, California.  ...
... areas provide many direct benefits to fisheries and coral ... limited help to corals in their battle against global ... coral reefs from climate change, marine protected areas need ... greenhouse gas emissions, researchers said. The new study, ...
... privately held therapeutic antibody company, today announced the addition ... to the company,s Therapeutic Advisory Board (TAB).  Drs. Lacey ... TAB, Jan de Vries, Ph.D. and Nicholas B. Lydon, ... AnaptysBio,s TAB is constituted to oversee the company,s ...
Cached Biology News:Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security 2Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security 3Rising ocean temperatures harm protected coral reefs 2Rising ocean temperatures harm protected coral reefs 3AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board 2AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board 3AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board 4
... The expertise that made the original Gene Pulser ... system available has been applied in the Gene ... The modular design of the Gene Pulser II ... accessory that has the widest range of settings ...
... and supplies, for 10 chips, provides ... perform protein analysis with 10 chips ... Supplied are 3 x 520 microliters ... 60 microliters Pro260 ladder (10-260 kD), ...
... and reliable automation for today's drug ... laboratories. Staccato Mini-Workstations offer the minimal ... liquid handling and material management tasks. ... Caliper's time proven CLARA™ assay development ...
...
Biology Products: